Summit Therapeutics Inc.
SMMT scores 26.8 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -15.8 points significantly impact the ranking. Without these adjustments, SMMT would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| SMMT | 26.8 | N/A | 0.0% | 0.0% | $11.9B |
| INCY | 89.6 | 15.8 | 21.2% | 25.0% | $20.1B |
| GMAB | 85.5 | 13.1 | 22.8% | 36.4% | $18.5B |
| CPRX | 82.2 | 13.7 | 23.5% | 37.6% | $3.0B |
| VRTX | 78.0 | 32.1 | 8.9% | 32.9% | $126.0B |
| ASND | 75.7 | 16.6 | 98.0% | -31.7% | $13.3B |
| NBIX | 74.7 | 26.5 | 21.4% | 16.7% | $12.5B |
| ALKS | 74.6 | 16.5 | -6.4% | 23.9% | $5.5B |
| AMGN | 73.8 | 26.0 | 10.0% | 21.0% | $199.0B |
| ARGX | 73.6 | 35.1 | 78.6% | 38.0% | $50.9B |
| HOLX | 73.3 | 31.1 | 1.7% | 13.8% | $16.8B |
| REGN | 72.7 | 19.4 | 1.0% | 31.4% | $84.9B |
| ISRG | 72.3 | 61.7 | 20.5% | 28.4% | $172.5B |
| EXEL | 71.9 | 15.1 | 7.0% | 33.7% | $11.7B |
| KRYS | 71.0 | 41.4 | 473.0% | 30.7% | $8.0B |
| HALO | 70.2 | 16.8 | 22.4% | 43.7% | $9.3B |
| Sector Average | 37.1 | 252.3 | 161.5% | -3292.7% | â |
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Stock is in a downtrend below the 200-day moving average. Price is below both the 50-day and 200-day SMAs, indicating sustained selling pressure.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $-4,355 | $-42,000 | $-37,000 | $-25,000 |
| Operating Income | $57M | $-234M | $-568M | $-67M |
| Net Income | $-219M | $-232M | $-566M | $-63M |
| EPS (Diluted) | $-0.28 | $-0.31 | $-0.76 | $-0.09 |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $2.23 | $8.70 | 118.4% | Wide |
| 2022 | $0.66 | $5.61 | 157.9% | Wide |
| 2023 | $1.25 | $5.78 | 128.9% | Wide |
| 2024 | $2.10 | $33.89 | 176.7% | Wide |
| 2025 | $15.55 | $36.91 | 81.4% | Wide |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.